These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18499335)

  • 41. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
    Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
    Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. External validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology among Japanese patients.
    Imamoto T; Suzuki H; Utsumi T; Takano M; Suyama T; Kawamura K; Kamiya N; Naya Y; Ueda T; Ichikawa T
    Urology; 2010 Aug; 76(2):404-10. PubMed ID: 19716590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of extraprostatic extension in men with biopsy Gleason score of 8 or greater.
    Nakanishi H; Troncoso P; Babaian RJ
    J Urol; 2008 Dec; 180(6):2441-5; discussion 2445-6. PubMed ID: 18930495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is there a relationship between prostate volume and Gleason score?
    Mir MC; Planas J; Raventos CX; de Torres IM; Trilla E; Cecchini L; Orsola A; Morote J
    BJU Int; 2008 Aug; 102(5):563-5. PubMed ID: 18476971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Positive predictive value of high-grade prostatic intraepithelial neoplasia in initial core needle biopsies of prostate adenocarcinoma--a study with complete sampling of hemi-prostates with corresponding negative biopsy findings.
    Delatour NL; Mai KT
    Urology; 2008 Sep; 72(3):623-7. PubMed ID: 18279923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy.
    Singh H; Canto EI; Shariat SF; Kadmon D; Miles BJ; Wheeler TM; Slawin KM
    J Urol; 2004 Mar; 171(3):1089-92. PubMed ID: 14767277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies.
    Briganti A; Tutolo M; Suardi N; Gallina A; Abdollah F; Capitanio U; Freschi M; Bianchi M; Salonia A; Colombo R; Rigatti P; Montorsi F
    Prostate; 2012 Jun; 72(8):925-30. PubMed ID: 21965006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
    Polascik TJ; Mayes JM; Schroeck FR; Sun L; Madden JF; Moul JW; Mouraviev V
    Cancer; 2009 May; 115(10):2104-10. PubMed ID: 19288576
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.
    Shukla-Dave A; Hricak H; Kattan MW; Pucar D; Kuroiwa K; Chen HN; Spector J; Koutcher JA; Zakian KL; Scardino PT
    BJU Int; 2007 Apr; 99(4):786-93. PubMed ID: 17223922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
    Schröder FH; van den Bergh RC; Wolters T; van Leeuwen PJ; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2010 Feb; 57(2):256-66. PubMed ID: 19913350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.
    Miyamoto H; Hernandez DJ; Epstein JI
    Hum Pathol; 2009 Dec; 40(12):1693-8. PubMed ID: 19683331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The contemporary concept of significant versus insignificant prostate cancer.
    Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
    Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.
    Suardi N; Capitanio U; Chun FK; Graefen M; Perrotte P; Schlomm T; Haese A; Huland H; Erbersdobler A; Montorsi F; Karakiewicz PI
    Cancer; 2008 Oct; 113(8):2068-72. PubMed ID: 18792067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk.
    Schiffmann J; Connan J; Salomon G; Boehm K; Beyer B; Schlomm T; Tennstedt P; Sauter G; Karakiewicz PI; Graefen M; Huland H
    Prostate; 2015 Jan; 75(1):45-9. PubMed ID: 25284155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
    Briganti A; Capitanio U; Chun FK; Gallina A; Suardi N; Salonia A; Da Pozzo LF; Colombo R; Di Girolamo V; Bertini R; Guazzoni G; Karakiewicz PI; Montorsi F; Rigatti P
    Eur Urol; 2008 Oct; 54(4):794-802. PubMed ID: 18514383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of prostate carcinoma stage by quantitative biopsy pathology.
    Veltri RW; Miller MC; Partin AW; Poole EC; O'Dowd GJ
    Cancer; 2001 Jun; 91(12):2322-8. PubMed ID: 11413521
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
    Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V
    Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.